References (Chapter 8)
References for “Assessing all the relevant, reliable evidence”:
1 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;332:349-60.
2 Reynolds LA, Tansey EM, eds. Prenatal corticosteroids for reducing morbidity and mortality after preterm birth. London: Wellcome Trust, Centre for the History of Medicine, 2005.
3 Dickersin K, Chalmers I. Recognising, investigating and dealing with incomplete and biased reporting of clinical research: from Francis Bacon to the World Health Organisation. James Lind Library 2010.
4 Cowley AJ, Skene A, Stainer K, et al. The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias. International Journal of Cardiology 1993;40:161-6.
6 Stjernswärd J. Decreased survival related to irradiation postoperatively in early operable breast cancer. Lancet 1974;ii:1285-6.
7 Stjernswärd J. Meta-analysis as a manifestation of ‘bondförnuft’ (‘peasant sense’). JLL Bulletin: Commentaries on the history of treatment evaluation 2009.
8 Fugh-Berman AJ. The haunting of medical journals: how ghostwriting sold “HRT”. PLoS Medicine 2010;7(9):e1000335.
9 Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin-reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-5.
10 Spielmans GI, Biehn TL, Sawrey DL. A case study of salami slicing: pooled analysis of duloxetine for depression. Psychotherapy and Psychosomatics 2010;79:97-106.
11 Antman EM, Lau J, Kupelnick B, et al. A comparison of results of metaanalysis of randomized control trials and recommendations of clinical experts. JAMA 1992;268:240-8.
12 Natanson C, Kern SJ, Lurie P, et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 2008;299(19):2304-12.
13 Chalmers I. TGN1412 and The Lancet’s solicitation of reports of phase 1 trials. Lancet 2006;368:2206-7.
15 Kenter MJH, Cohen AF. Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet 2006;368:1387-91.
16 McLellan F. 1966 and all that – when is a literature search done? Lancet 2001;358:646.
17 Horn J, Limburg M. Calcium antagonists for acute ischemic stroke. Cochrane Database of Systematic Reviews 2000, Issue 1. Art. No.:
18 Horn J, de Haan RJ, Vermeulen M, et al. Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review. Stroke
19 O’Collins VE, Macleod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke. Annals of Neurology 2006;59:467-77.
20 CRASH trial collaborators. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury – outcomes at 6 months. Lancet 2005;365:1957-9.